MOA Magnifiers

Ibrutinib: an Inhibitor of Bruton’s Tyrosine Kinase

Mechanism of Action Magnifier – 2016 Desk Reference

Duvelisib (IPI-145): a Dual Inhibitor of Phosphoinositide 3-Kinase (PI3K)-Delta and -Gamma

Mechanism of Action Magnifier – 2016 Desk Reference

Blinatumomab: a Bispecific CD19-Directed CD3 T-Cell Engager

Mechanism of Action Magnifier – 2016 Desk Reference

Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway

Mechanism of Action Magnifier – 2016 Desk Reference

Magnifying Mechanisms of Action: an Exclusive Series to PMO

By Al B. Benson III, MD

Mechanism of Action Magnifier – 2016 Desk Reference

Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.

Page 2 of 2

1
2